Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Jul 15, 2019

SELL
$1.8 - $3.3 $2,586 - $4,742
-1,437 Closed
0 $0
Q1 2019

Apr 02, 2019

BUY
$2.41 - $5.91 $187 - $460
78 Added 5.74%
1,437 $4,000
Q3 2018

Oct 16, 2018

BUY
$8.6 - $11.26 $11,687 - $15,302
1,359 New
1,359 $13,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track First Hawaiian Bank Portfolio

Follow First Hawaiian Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Hawaiian Bank, based on Form 13F filings with the SEC.

News

Stay updated on First Hawaiian Bank with notifications on news.